GENEVA, Switzerland, Jan. 21 /PRNewswire-FirstCall/ -- GeneProt Inc. announced today that it has signed an agreement with Serono under which Serono will test a set of novel datamined polypeptides and proteins discovered and synthesized chemically by GeneProt. Serono has an option to obtain an exclusive license to any of polypeptides and proteins supplied by GeneProt under the agreement. Financial terms were not disclosed.
"We are very pleased with this opportunity to push our products further down the discovery pipeline. This is GeneProt's second Pharma / Biotech deal. In November 2000, Novartis signed a US$41 million five-year research program carried out at GeneProt," said Bertrand Damour, GeneProt's CFO and Co-Chairman of the Operating Committee.
"These proteins and polypeptides were discovered through our own datamining capability and were synthesized chemically in multimilligram quantities in high purity," said Keith Rose, GeneProt's CSO.
About GeneProt(TM) - GeneProt, Inc. is an industrial-scale proteomics company focused on separating, identifying, characterizing, selecting and synthesizing certain human proteins on behalf of life sciences companies and for its own account for use in the discovery and development of new therapeutic proteins, protein drug targets and protein biomarkers. It is also involved in datamining. |
